Biotech Stocks Facing FDA Decision In July 2025

July is poised to be a pivotal month for the pharmaceutical sector, with numerous key FDA regulatory decisions and advisory committee meetings anticipated. Regeneron (REGN) awaits decisions on two oncology assets, Linvoseltamab and Odronextamab, following prior resubmissions, while Dizal's Sunvozertinib for NSCLC and Replimune's (REPL) RP1 for melanoma are also under review. Investors will closely monitor Roche's (RHHBY.OB) Columvi label expansion for DLBCL, which faces a decision despite a recent FDA panel's negative recommendation, and GSK's (GSK) Blenrep combinations for multiple myeloma, given the drug's prior market withdrawal. Additional notable decisions include Otsuka's (OTSKY.OB) REXULTI, Sobi's (SWOBY.OB) DOPTELET, Ascendis Pharma's (ASND) Skytrofa, Apellis' (APLS) EMPAVELI, and PTC Therapeutics' (PTCT) Sepiapterin, collectively influencing near-term market dynamics for these biopharmaceutical companies.

Analysis

July presents a series of high-stakes, binary-event catalysts for the biopharmaceutical sector, centered on key FDA decisions. Regeneron (REGN) awaits verdicts on two oncology therapies, Linvoseltamab and Odronextamab, both of which are resubmissions following prior rejections for non-clinical issues related to manufacturing and trial enrollment, suggesting a potentially clearer path to approval this time. Conversely, Roche (RHHBY.OB) and GSK face significant headwinds; Roche's Columvi label expansion received a negative recommendation from an FDA panel concerned about the trial data's applicability to the U.S. population, despite a reported 41% survival benefit. GSK is seeking re-approval for Blenrep, a drug previously withdrawn from the market in 2022 after a confirmatory trial failure, making its PDUFA date exceptionally risky. Other notable events include label expansions for established, revenue-generating assets, such as Ascendis Pharma's (ASND) Skytrofa, which saw sales grow to €202 million in 2024, and Apellis' (APLS) EMPAVELI, which is under priority review. Companies with novel therapies, including Replimune's (REPL) RP1 for melanoma and PTC Therapeutics' (PTCT) Sepiapterin for PKU, also face critical decisions that could validate their platforms and unlock new markets.

Key Decisions for Investors

• Investors should exercise caution with Roche (RHHBY.OB) and GSK, as the negative FDA panel opinion on Columvi and Blenrep's prior market withdrawal represent significant approval hurdles.
• Regeneron (REGN) offers a more favorable risk profile, as its two upcoming decisions are for resubmissions where the original rejections were based on correctable, non-clinical issues, increasing the probability of approval.
• Consider the lower-risk growth potential in Ascendis Pharma (ASND) and Apellis (APLS), whose catalysts are label expansions for already commercialized drugs with existing revenue streams.
• Traders focused on binary events should note the high volatility potential in Replimune (REPL) and PTC Therapeutics (PTCT), where an FDA approval would serve as a major validation for their respective therapeutic platforms.